Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas
Journal of Neuropathology & Experimental Neurology · 2025
DOI: 10.1093/jnen/nlaf058 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2025. Verfasst von Sofie Eline Tollefsen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondh…. Hauptthemen laut MEDLINE: Meningioma, Neurofibromin 2, Meningeal Neoplasms, Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Norwegian University of Science and Technology.
Abstract (Originalsprache)
Deletion in 22q and mutations in the neurofibromatosis type 2 (NF2) gene are frequent in sporadic meningiomas. The tumor suppressor protein merlin is encoded by NF2, and mutations may promote tumor development. NF2 status is increasingly important in meningioma diagnostics and we questioned whether merlin immunohistochemistry could be used as an accessible and affordable surrogate marker for prediction of NF2 mutations. Previous studies on merlin immunoreactivity have reported diverging results. We aimed to describe the immunohistochemical expression of merlin in a large series of meningiomas and relate these findings to clinicopathological features and NF2 status. Standardized immunohistochemistry was conducted on 172 meningiomas using three different merlin antibodies directed toward the N-terminal, C-terminal and phospho-merlin (ser 518). Twenty of the included cases had known NF2 status. All tumor specimens were immunoreactive for the three merlin antibodies. The immunoreactivity of phosphorylated merlin was higher in meningothelial tumors. There were no other significant associations between merlin immunoreactivity and NF2 status, WHO grade, tumor subtype, tumor location or gender. These results indicate that merlin immunoreactivity does not seem to be predictive of NF2 mutation, as merlin was abundantly expressed by all included tumors and independently of NF2 status.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
- Department of Neurosurgery, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
- Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway.
- Department of Pathology, St Olavs Hospital, Trondheim, Norway.
- Department of Medical Genetics, St Olavs Hospital, Trondheim, Norway.
ORCID-Profile: Sofie Eline Tollefsen, Rahmina Meta, Ole Solheim, Patricia Mjønes, Ingfrid Vestrheim, Sverre Helge Torp
Förderung
- Norwegian University of Science and Technology
Zitieren
APA
Tollefsen, S. E., Meta, R., Solheim, O., Mjønes, P., Vestrheim, I., Sjursen, W., & Torp, S. H. (2025). Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlaf058
Vancouver
Tollefsen SE, Meta R, Solheim O, Mjønes P, Vestrheim I, Sjursen W, et al. Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas. Journal of Neuropathology & Experimental Neurology. 2025. doi:10.1093/jnen/nlaf058
BibTeX
@article{Tollefsen2025,
author = {Tollefsen, Sofie Eline and Meta, Rahmina and Solheim, Ole and Mjønes, Patricia and Vestrheim, Ingfrid and Sjursen, Wenche and Torp, Sverre Helge},
title = {Merlin immunoreactivity fails to predict neurofibromatosis type 2 mutations in human meningiomas},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2025},
doi = {10.1093/jnen/nlaf058}
}
EUVIMED